Designing biologics for commercial success
Justyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readiness.
The path from biologics development to commercial manufacturing is becoming increasingly complex. Developers must balance accelerated timelines, evolving regulatory expectations, and increasing pressure to reduce cost of goods while maintaining product quality and supply reliability.
While early development often focuses on achieving the desired biological outcome, manufacturing success depends on far more than molecule performance. As programs advance toward GMP manufacturing and commercialization, scalability, reproducibility, process robustness, and operational efficiency become critical determinants of long-term success.
Late-stage challenges
Late-stage development brings together process validation, technology transfer, analytical comparability, manufacturing readiness, and regulatory compliance under compressed timelines. Decisions made at laboratory scale can become significant operational constraints at manufacturing scale, increasing complexity, extending timelines, and reducing manufacturing efficiency.
For many organizations, these challenges emerge too late to be addressed without additional development work or manufacturing delays. The ability to anticipate potential risks and design processes with commercial execution in mind is becoming an essential component of successful biologics development.
An integrated approach
Late-stage efficiency starts with early collaboration between process development, analytical development, Manufacturing Science & Technology (MS&T), manufacturing, quality, and regulatory teams.
Integrating these functions early enables organizations to establish stronger process understanding, identify manufacturing risks sooner, and design processes that are scientifically robust and operationally practical. The result is greater manufacturing readiness, improved process robustness, and increased confidence as biologics programs transition from development to commercial supply.
Technology transfer also benefits from this integrated model. When development and manufacturing teams work within a connected framework, process knowledge, analytical methods, and operational experience transfer efficiently across functions, reducing variability and supporting smoother implementation at GMP scale.
As biologics grow in complexity, successful commercialization will increasingly depend on development strategies that embed manufacturability from the early stages. Integrating scientific expertise with manufacturing knowledge throughout the product lifecycle reduces development risk, improves operational efficiency, and establishes a stronger foundation for long-term commercial success.
Integrated biologics services
Rezon Bio supports biotech and biopharma companies across the entire biologics product lifecycle.
- Cell line development
- Process development
- Analytical development
- Technology transfer
- Formulation development
- Clinical & commercial manufacturing
- Regulatory CMC support
One integrated team. One development strategy. One seamless path to your commercial success.
Meet our expert
Justyna Adamczyk, Associate VP Integrated MS&T
Justyna specializes in biologics manufacturing, process scale-up, tech transfer, and MS&T, with 15+ years of experience across mammalian and microbial systems. She supports multidisciplinary teams in scaling processes, validating manufacturing, and ensuring efficient transfer from development to GMP production while ensuring regulatory compliance.
This article is sponsored by Rezon Bio.
